InCephalo AG

InCephalo is a preclinical stage biotech company founded in May 2021. InCephalo's six (6) founders with various backgrounds came together with the vision of making a difference in the lives of those being diagnosed with brain cancer. The founders experienced first-hand what it means if someone important to them gets diagnosed with this disease. The founding team has complementary competencies and consists of academics, a neurosurgeon, a legal expert, and a biotech entrepreneur. Since its foundation, the company convinced world-renown neurosurgeons, neuro-oncologists, preclinical, clinical, and regulatory experts to join them. The company focuses on developing antibodies and other biological treatments for the local treatment of CNS cancers. Its primary drug candidate recieved EMA ODD.